Published in

Kachestvennaya klinicheskaya praktika, 4S, p. 103-105, 2020

DOI: 10.37489/2588-0519-2020-s4-103-105

Links

Tools

Export citation

Search in Google Scholar

Rationale for use mefloquine for COVID-19 treatment

Journal article published in 2020 by V. A. Otdelenov ORCID, K. B. Mirzaev ORCID, A. V. Dmitriev ORCID, V. V. Poroikov ORCID, D. A. Sychev ORCID
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Question mark in circle
Preprint: policy unknown
Upload
Question mark in circle
Postprint: policy unknown
Upload
Question mark in circle
Published version: policy unknown
Upload

Abstract

Currently, the use of mefloquine in patients with COVID-19 does not have sufficient scientific justification and, given the unfavorable efficacy and safety profile, cannot be considered for routine use in clinical practice.